Abstract: The present disclosure concerns a Protein Quantification Reporter (PQR) linker which is capable of being cleaved during the translation of a messenger RNA to quantify a protein of interest. The PQR linker can encode a peptide of SEQ ID NO: 23 and have the nucleic acid sequence of SEQ ID NO: 25. The PQR linker is located in a nucleic acid molecule encoding a poly-protein between a reporter protein and the protein of interest. While the messenger RNA encoding the poly-protein is being translated, the presence of the PQR linker causes cleavage of the poly-protein and consequently the release at a stoichiometric ratio of the reporter protein and the protein of interest. The signal associated with the cleaved reporter protein can be measured to estimate or quantify the protein of interest.
Abstract: An isolated and/or artificial pG1-x promoter, which is a functional variant of the carbon source regulatable pG1 promoter of Pichia pastoris identified by SEQ ID 1, which pG1-x promoter consists of or comprises at least a part of SEQ ID 1 with a length of at least 293 bp, characterized by the following promoter regions: a) at least one core regulatory region comprising the nucleotide sequences SEQ ID 2 and SEQ ID 3; and b) a non-core regulatory region, which is any region within the pG1-x promoter sequence other than the core regulatory region; wherein the pG1-x promoter comprises at least one mutation in any of the promoter regions and a sequence identity of at least 80% in SEQ ID 2 and SEQ ID 3, and a sequence identity of at least 50% in any region other than SEQ ID 2 or SEQ ID 3; and further wherein the pG1-x promoter is characterized by the same or an increased promoter strength and induction ratio as compared to the pG1 promoter, wherein the promoter strength is at least 1.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
August 25, 2020
Assignee:
LONZA LTD
Inventors:
Diethard Mattanovich, Brigitte Gasser, Roland Prielhofer
Abstract: The invention provides a series of peptide signals which, when linked to a polypeptide of interest (POI), ensure that said polypeptide is secreted in high yields by a host cell such as Mycoplasma pneumoniae. The invention also provides fusion proteins tagged with said peptide signals, the nucleic acid sequences coding for them, host cells comprising said tagged fusion proteins and a variety of uses of the fusion proteins and the host cells.
Type:
Grant
Filed:
February 26, 2016
Date of Patent:
August 18, 2020
Assignees:
FUNDACIÓ CENTRE DE REGULACIÓ GENÓMICA (CRG), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Inventors:
Bernhard Paetzold, Maria Lluch Senar, Luis Serrano Pubul
Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and/or a 3?UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
Abstract: The present invention relates to a method of diagnosing depression (even at an early stage that may precede clinical symptoms), for determining the pharmacoresponse to antidepressants, for managing treatment of psychiatric disorders, including depression, and for treatment of depression in patients. Further provided is a method for screening antidepressants.
Abstract: The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.
Type:
Grant
Filed:
September 12, 2017
Date of Patent:
August 4, 2020
Assignee:
Veracyte, Inc.
Inventors:
Giulia C. Kennedy, Darya I. Chudova, Eric T. Wang, Jonathan I. Wilde
Abstract: Methods and kits for selectively enriching non-random polynucleotide sequences are provided. Methods and kits for generating libraries of sequences are provided. Methods of using selectively enriched non-random polynucleotide sequences for detection of fetal aneuploidy are provided.
Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
July 21, 2020
Assignee:
Hummingbird Diagnostics GmbH
Inventors:
Andreas Keller, Benjamin Meder, Hugo Katus, Britta Vogel, Markus Beier
Abstract: Provided is a method for synthesizing a protein, into which a nucleobase amino acid (NBA) is introduced at a desired position, that comprises: a step for preparing mRNA into which a modified codon is inserted at a desired position downstream of an initiation codon; and a step for translating the aforesaid mRNA into a protein in the presence of tRNA, said tRNA recognizing the modified codon and being acylated with the NBA. Also provided is a ribozyme that catalyzes the aminoacylation of tRNA and comprises two RNA molecules.
Type:
Grant
Filed:
June 8, 2016
Date of Patent:
July 14, 2020
Assignee:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
Abstract: A biological detection method for dioxin compounds in serum and its diagnostic use in predicting metabolic syndrome and related conditions are disclosed. The method of detecting dioxin compounds include obtaining a serum sample by heat-inactivating total serum obtained from a subject, preparing a transformed cell line by introducing a recombinant vector comprising a gene construct in which at least one dioxin-responsive element is operably linked to a promoter and a reporter gene into a host cell, culturing the transformed cell line with the serum sample, detecting the activation of the reporter gene in the transformed cell line, and determining that the dioxin compound is included in the serum sample when the activation of the reporter gene is detected. The serum detected by the method can be used as a surrogate serum biomarker to correlate serum content with disease factors and to predict the occurrence of disease and determine treatability.
Type:
Grant
Filed:
May 20, 2019
Date of Patent:
June 30, 2020
Assignees:
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
June 16, 2020
Assignee:
CureVac AG
Inventors:
Andreas Thess, Thomas Schlake, Jochen Probst
Abstract: The present invention relates in general to bacterial cells having genetic alterations that result in increased expression of a protein of interest and methods of making and using such cells. Aspects of the present invention include altered Gram positive microorganisms having one or more a genetic alterations that reduce the expression of a gene in the sin operon, thereby resulting in the enhanced expression of one or more proteins of interest.
Type:
Grant
Filed:
December 3, 2015
Date of Patent:
June 16, 2020
Assignee:
DANISCO US INC
Inventors:
Cristina Bongiorni, Rodante Gonzales Caguiat, Carol Marie Fioresi, Brian F. Schmidt, Anita Van Kimmenade, Chao Zhu
Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
Type:
Grant
Filed:
December 19, 2017
Date of Patent:
June 2, 2020
Assignee:
SELEXIS S.A.
Inventors:
Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
Abstract: Materials and methods for improving plant traits and for providing plant fitness benefits are provided. In some embodiments, the materials, and methods employing the same, can comprise endophytes.
Type:
Grant
Filed:
December 30, 2015
Date of Patent:
June 2, 2020
Assignee:
Indigo Ag, Inc.
Inventors:
Karen V. Ambrose, Nathan A. Billings, Slavica Djonovic, Richard Bailey Flavell, Trudi A. Gulick, David Morris Johnston, Jonathan W. Leff, Stephanie M. Liva, Jeffrey Lyford, Geoffrey Von Maltzahn, Luis Miguel Marquez, Yves Alain Millet, Craig Sadowski, Phillip Samayoa, Gerardo V. Toledo, David R. Weisman, Xuecheng Zhang
Abstract: The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis.
Type:
Grant
Filed:
March 14, 2019
Date of Patent:
June 2, 2020
Assignee:
Veracyte, Inc.
Inventors:
Giulia C. Kennedy, Darya I. Chudova, Eric T. Wang, Jonathan I. Wilde, Bonnie H. Anderson, Hui Wang, Moraima Pagan, Nusrat Rabbee
Abstract: The present invention relates to a new strain of Clostridium acetobutylicum modified to be unable to produce hydrogen and its use for the continuous production of bulk chemicals such as lactate, 1,3-propanediol, ethanol, butanol, isobutanol, 1,3-butanediol, acetate, acetone, isopropanol, 3-hydroxy-3-methylbutyrate and isobutene at high yield.
Type:
Grant
Filed:
September 18, 2015
Date of Patent:
June 2, 2020
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DES SCIENCES APPLIQUEES, INSTITUT NATIONAL DE A RECHERCHE AGRONOMIQUE
Inventors:
Philippe Soucaille, Ngoc-Phuong-Thao Nguyen, Benjamin Percheron, Christian Croux, Isabelle Meynial-Salles
Abstract: The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.
Type:
Grant
Filed:
May 6, 2015
Date of Patent:
June 2, 2020
Assignee:
Berg LLC
Inventors:
Niven Rajin Narain, Indushekhar Persaud, John Patrick McCook
Abstract: The present invention relates to methods comprising whole genome sequencing for identifying polymorphisms in samples comprising mixtures of genomes, and for determining and/or monitoring the presence or absence of disorders associated with the identified polymorphisms.